1. Home
  2. Material Detail: BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

Material Detail

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

Germline mutations in the BRCA1 or BRCA2 genes are associated with an increased risk of breast and ovarian cancer development. Both genes are involved in DNA repair, and tumors harboring genetic defects in them are thought to be more sensitive to DNA-damaging ...

Show More
Disciplines:
Go to Material 
Bookmark / Add to Course ePortfolio
Create a Learning Exercise
Add Accessibility Information
Rate
Add a Comment

Quality

  • User Rating
  • Comments
  • Learning Exercises
  • Bookmark Collections
  • Course ePortfolios
  • Accessibility Info

More about this material

Material Type:
Open (Access) Journal-Article
Date Added to MERLOT:
July 23, 2024
Date Modified in MERLOT:
July 31, 2024
Author:
Submitter:
L. Williams
Primary Audience:
High School, College General Ed, College Upper Division
Technical Format:
Website
Mobile Compatibility:
Not specified at this time
Language:
English
Cost Involved:
Unknown
Source Code Available:
Unknown
Creative Commons:
Unknown

Browse...

Disciplines with similar materials as BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
People who viewed this also viewed
Other materials like BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.